CD19 and primary central nervous system lymphoma: CD19-targeted CAR-T cells have been successfully used to treat B-cell leukemia and lymphoma [40–42], however, their potential in PCNSL has not been fully explored, partly due to complications associated with treatment and partly due to specific and complex expression patterns of target molecules in the brain microenvironment [43].